Johnson & Johnson Posts Strong Q3 with $5.15B Net Earnings, Lifts 2025 Outlook
J&J posted $24B in Q3 sales and $2.80 adjusted EPS, beating estimates and raising full-year guidance.
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Johnson & Johnson reported Q4 2025 revenue of $24.6 billion, beating expectations, while EPS came in at $2.46, just below forecasts.
J&J posted $24B in Q3 sales and $2.80 adjusted EPS, beating estimates and raising full-year guidance.
Johnson & Johnson (JNJ) surpassed expectations in Q2 2025 with a notable increase in earnings per share and revenue.
Johnson & Johnson's first-quarter results surpassed expectations with notable growth in sales and earnings.
Johnson & Johnson faces a significant legal setback with the dismissal of its $10 billion settlement proposal related to talc product lawsuits.
Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19.
Johnson & Johnson (NYSE: JNJ) reported a 4.3% increase in sales to $22.4 billion in Q2 2024, with operational growth at 6.6% and adjusted EPS rising…
Johnson & Johnson (NYSE: JNJ) reported a 2.3% increase in sales to $21.4 billion for Q1 2024.
Johnson & Johnson exceeded the anticipated earnings per share (EPS) of $2.28, showcasing operational efficiency and resilience in a complex global business environment.